Drugs / Nusivertib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04176198 | Dec 2019 → Apr 2027 expected | myelofibrosis | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nusivertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176198 ↗ |
| Action | Inhibit | “Oral PIM Inhibitor” NCT04176198 ↗ |
| Route | Oral | “Oral PIM Inhibitor” NCT04176198 ↗ |